Reach Us +1-504-608-2390
Isoform-Selective HDAC Inhibition in Autoimmune Disease | OMICS International | Abstract
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Review Article

Isoform-Selective HDAC Inhibition in Autoimmune Disease

Nicole L Regna1* and Christopher M Reillya2
1Department of Biomedical Sciences & Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, 24061, USA
2Edward Via College of Osteopathic Medicine, Blacksburg, VA, 24060, USA
Corresponding Author : Nicole Regna
Center for Molecular Medicine and Infectious Diseases (CMMID)
Virginia-Maryland Regional College of Veterinary Medicine
1410 Prices Fork Road, Blacksburg, VA, 24061, USA
Tel: (434) 609-2703
Fax: (540) 231-3426
E-mail: [email protected]
Received March 04, 2014; Accepted April 07, 2014; Published April 14, 2014
Citation: Regna NL, Reillya CM (2014) Isoform-Selective HDAC Inhibition in Autoimmune Disease. J Clin Cell Immunol 5:207. doi: 10.4172/2155-9899.1000207
Copyright: © 2014 Regna NL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google


Histone deacetylases are a class of enzymes that play an important role in protein modification and cellular function. Ongoing research suggests that HDAC inhibitors may be efficacious in the treatment of a wide range of diseases from cancer to autoimmune disease. HDACi therapy has shown promising results both in vitro and in vivo for the treatment of autoimmune disease. To date, 18 isoforms of HDACs have been identified, which exist in four different classes: class I (HDAC1, 2, 3, and 8), class II (HDAC4, 5, 6, 7, 9, and 10) class III (sirtuins1-7), and class IV (HDAC11). The mechanism of action through which HDACs function remains to be fully elucidated. However, the use of isoform-selective HDAC inhibitors has been helpful in determining the physiological role of individual HDACs as well as in decreasing the toxicity of HDACi therapy. This review will focus on isoform-selective HDACs and how they may be effective for the treatment of autoimmune disease.